locking in updates

claude_rewrite
youainti 4 years ago
parent 3e62e33fae
commit 4253288513

@ -2,19 +2,21 @@
\graphicspath{{\subfix{Assets/img/}}}
\begin{document}
%Classes of data
% Trial Dynamics/snapshots
% Drugs on Market
% Market/Population Size
% Compounds, interactions
\subsection{Data Sources}
The following are the data source I plan on using.
\subsubsection{Clinical Trials Data}
%ClinicalTrials.gov
% Key features - brief description
% Snapshots
% Why is it being included
% What specific data is used
% Enrollment, status, duration, indication, compound
% Data Manipulations for each
% Normalized: Enrollment, duration
% Categorical-to dummies: status
% Linked: indication, compound
% counts: number of sponsor changes since start.
% Links to data
\subsubsection{Drugs on Market}
@ -22,7 +24,10 @@
% Key features
% Why is it being included
% What specific data is used
% compound, spl, marketing dates
% Data Manipulations for each
% Linked: compound, spl -> indication
% standardize start/end dates by getting a view: compound, dates, manufacturer.
% Links to data
\subsubsection{Global Disease Burden Survey}
@ -49,6 +54,6 @@
% Link Global disease burden to a generic indication registry
% Link trial compounds a generic registry (MPT or whatever that was)?
% Link SPL compounds to a generic registry
%
% Link Market data to SPLs
\end{document}

@ -2,11 +2,59 @@
\graphicspath{{\subfix{Assets/img/}}}
\begin{document}
In September of 2019, the European Space Agency (ESA) released a tweet
explaining that they had performed an appendicotomy in space using
nothing more than radiation from the sun.
They are sad to announce that the patient died due to complications from
exposure to the cold vaccum of space.
%% Describe goal
% Estimate probability distribution of normalized durations and conclusion statuses.
% Explain why this answers questions well.
% How do I propose estimating that?
%%NOTATION
First, some notation:
\begin{itemize}
\item $t,i$ index trial and snapshot of the trial respectively.
\item $S_{it}$ : status (``Terminated'', ``Concluded'')
at the conclusion of the trial
\item $\tau_{it}$ : elapsed percentage of planned duration, i.e. the normalized elapsed duration.
\item $s_{it}$: current status variable(s) describing current trial status as one of:
``Recruiting'', ``Active, not recruiting'', or ``Suspended''
\item $X_{it}$: data describing the trial at the snapshot level
\begin{itemize}
\item number of sponsor changes so far
\item percentage currently enrolled of planned enrolled
\end{itemize}
\item $M_{t}$: data describing market conditions at the time of the snapshot.
\begin{itemize}
\item number of compounds approved for the same indication
\item total number of marketers approved for the same indication
\item number of marketers for this specific compound
\end{itemize}
\item $T_t$: Trial Level Data
\begin{itemize}
\item Indication or indication class
\item Sponsor Type
\end{itemize}
\end{itemize}
Other variables used when selecting trials to include as observations are:
\begin{itemize}
\item Trial Phase\footnote{
Conditioning on previous trials can be as simple as selecting only
phase 2 or phase 3 trials.
}.
\item Does the trial have a Data Monitoring Committee?
\item Are the compounds an FDA regulated drug?
\end{itemize}
The goal is to estimate the probability distribution of conclusion status and duration conditional on the active snapshot status.
\begin{align}
\pr{ t, S | X,M,T} = \sum_{S\in\{\text{Terminated},\text{Concluded}\}} \pr{t|S,X,M,T} \pr{S|X,M,T}
\end{align}
Note how this has two component parts:
\begin{itemize}
\item The survival probability portion $\pr{t|S,X,M,T}$
\item The conclusion status portion $\pr{S|X,M,T}$
\end{itemize}
\end{document}

@ -18,3 +18,4 @@
%Math Operators
\DeclareMathOperator{\argmax}{argmax}
\DeclareMathOperator{\argmin}{argmin}
\newcommand{\pr}[1]{\ensuremath{\text{Pr}\left( #1 \right)}}

@ -1,9 +1,9 @@
\begin{tikzpicture}
\begin{pgfonlayer}{nodelayer}
\node [style=emptyBox] (0) at (-18.5, 4) {Compound Safety};
\node [style=emptyBox] (1) at (-18.5, -3.5) {Compound Effectiveness};
\node [style=Red Box] (3) at (-3.75, -3.5) {\begin{tabular}{l} Conclusion \\ $\bullet$ Status\\ $\bullet$ Duration \\ $\bullet$ Enrollment \end{tabular}};
\node [style=Red Box] (4) at (-2.75, 1) {\begin{tabular}{l} Snapshot \\ $\bullet$ Status\\ $\bullet$ Duration \\ $\bullet$ Enrollment \end{tabular}};
\node [style=emptyBox] (1) at (-18.5, -3.5) {Compound Effecacy};
\node [style=Red Box] (3) at (-3.5, -4.25) {\begin{tabular}{l} Conclusion State \\ $\bullet$ Status\\ $\bullet$ Duration \\ $\bullet$ Enrollment \end{tabular}};
\node [style=Red Box] (4) at (-2, 1) {\begin{tabular}{l} Snapshot State \\ $\bullet$ Status\\ $\bullet$ Duration \\ $\bullet$ Enrollment \end{tabular}};
\node [style=Red Box] (5) at (3.25, -2) {Market Conditions};
\node [style=Box] (6) at (-17.5, -5.5) {Sponsor Changes};
\node [style=Box] (7) at (-15.25, 0.25) {\begin{tabular}{l}Prior \\ Trials \end{tabular}};
@ -11,9 +11,9 @@
\node [style=emptyBox] (10) at (3.25, -5.25) {Unobserved};
\node [style=Box] (11) at (3.25, -6.25) {Observed: Control};
\node [style=Red Box] (12) at (3.25, -7.25) {Observed: Of interest};
\node [style=emptyBox] (13) at (-11, 4) {Adverse Events};
\node [style=emptyBox] (13) at (-11, 4) {Current Adverse Events};
\node [style=emptyBox] (14) at (-10.5, -1.5) {Measured Effectiveness};
\node [style=Box] (15) at (3.75, 1) {Disease Burden};
\node [style=Box] (15) at (4.75, 1) {Disease Burden};
\end{pgfonlayer}
\begin{pgfonlayer}{edgelayer}
\draw [style=RightArrow] (4) to (3);

Loading…
Cancel
Save